Silexion Therapeutics Announces 1-for-10 Reverse Stock Split Effective May 29 to Maintain Nasdaq Listing

summarizeSummary

Silexion Therapeutics announced a 1-for-10 reverse stock split, effective May 29, 2026, primarily to meet Nasdaq's minimum bid price requirement and facilitate future financing efforts.

check_boxKey Events

• Reverse Stock Split Effective

  A 1-for-10 reverse share split will become effective after market close on May 28, 2026, with trading on a split-adjusted basis beginning May 29, 2026.

• Nasdaq Compliance

  The primary purpose of the reverse split is to enable the company to maintain compliance with Nasdaq's minimum bid price requirement (Rule 5550(a)(2)).

• Enables Future Financing

  The company expects a higher per-share trading range to reduce volatility, broaden the investor base, and improve flexibility to fund the advancement of its lead product candidate, SIL204.

• Follows Shareholder Approval

  This action follows shareholder approval received on May 5, 2026, for the reverse stock split and an increase in authorized shares, after an initial rejection of similar proposals in March.

auto_awesomeAnalysis

Silexion Therapeutics is implementing a 1-for-10 reverse stock split, effective May 29, 2026. This action is critical for the company to regain compliance with Nasdaq's minimum bid price requirement, a necessary step given its recent 'going concern' warnings and stated need for future dilutive financing. Without this split, the company faced a high risk of delisting, which would severely impede its ability to raise capital and continue operations, particularly as it approaches a Phase 2/3 clinical trial for SIL204.